D.E. Shaw & Co’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

D.E. Shaw & Co’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-150,000	Closed	-$18K	–	4867
2024 Q4	$18K	Hold	150,000	–	–	﹤0.01%	4249
2024 Q3	$15.6K	Hold	150,000	–	–	﹤0.01%	4357
2024 Q2	$16.7K	Hold	150,000	–	–	﹤0.01%	4282
2024 Q1	$22.5K	Hold	150,000	–	–	﹤0.01%	4114
2023 Q4	$22.5K	Hold	150,000	–	–	﹤0.01%	4064
2023 Q3	$42K	Hold	150,000	–	–	﹤0.01%	3931
2023 Q2	$34.5K	Hold	150,000	–	–	﹤0.01%	3913
2023 Q1	$27K	Buy	+150,000	New	+$23.3K	﹤0.01%	4104

D.E. Shaw & Co's BLACR Position: Q1 2025 in Review

D.E. Shaw & Co sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 150,000 shares — an estimated $18K sold.

D.E. Shaw & Co first reported a position in BLACR in Q1 2023 and held it in 8 quarters. The position peaked at $42K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

D.E. Shaw & Co reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
D.E. Shaw & Co sold 150,000 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $18K.
D.E. Shaw & Co first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 8 quarters.
D.E. Shaw & Co's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $42K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on D.E. Shaw & Co's 13F filing for Q1 2025, filed 15 May 2025.